Datar Genetics

What Datar Genetics does

Datar Cancer Genetics is a multinational molecular oncology diagnostics company operating CAP- and CLIA-accredited clinical laboratories in Nashik, India and Guildford, UK. Founded in 2013 around circulating tumour cell (CTC) research, the company focuses on non-invasive, blood-based cancer testing and serves clinicians, hospitals, academic medical centres, biopharmaceutical partners, and direct-to-consumer patients across the full cancer care continuum — screening, diagnosis, therapy guidance, and post-treatment monitoring. Its commercial footprint spans India, the UK, Germany, Kuwait, the US, and South Africa, supported by CE marking, three FDA Breakthrough Device Designations, and a May 2026 FDA clearance.

The portfolio comprises eight core diagnostic products built on three technology pillars: CTC detection via immunocytochemistry (Trublood, EasyCheck360, Pinaka), dual-analyte DNA and RNA next-generation sequencing with comprehensive genomic profiling (CellDx-Tissue, Exacta, Cancertrack, Target-MRD), and in-vitro chemosensitivity profiling on live tumour cells (Chemoscale). CellDx-Tissue is the first FDA-cleared tissue-based comprehensive genomic profiling assay of its class, analysing 517 cancer-associated genes. Exacta integrates 400 genes and 20,802 gene expression perturbations through an AI-driven decision support layer to recommend personalised therapies. Validated performance metrics include Trublood's 94.6% overall accuracy and approximately 20% additional actionable fusion detection from the dual-analyte sequencing workflow.

Datar monetises through per-test laboratory diagnostic services with quote-based pricing, accepting payments via SWIFT, NEFT/RTGS/IMPS, UPI/PhonePe, and the CCAvenue online gateway. The go-to-market combines enterprise field sales to oncologists and hospitals, a direct-to-consumer website (datarpgx.com), and channel partnerships — including UK hospital relationships with Cromwell Hospital and The London Clinic and a 2022 regional distribution agreement with Kuwait's Virtus Group. The company is promoter-controlled by Rajan Datar, appears bootstrapped with only one disclosed funding event (2014, Brand Capital, amount undisclosed), and has built scientific credibility through more than 80 peer-reviewed publications spanning 2016-2023.

Name

Datar Genetics

Legal name

Datar Cancer Genetics Ltd

Website

https://datarpgx.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

Datar Cancer Genetics operates CAP- and CLIA-accredited molecular oncology laboratories in India and the UK, delivering non-invasive blood-based cancer diagnostics spanning screening, diagnosis, therapy guidance, and monitoring to clinicians, hospitals, patients, and biopharma partners worldwide.

Ownership category

akta.pro rank

Product category

Molecular Oncology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Molecular oncology diagnostics
• Genomic profiling services
• Liquid biopsy testing
• Cancer screening solutions
• Precision oncology tests

Headquarters

HQ city

Nasik

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Laboratory Diagnostic Testing Services: The company operates CAP-accredited and CLIA-accredited laboratories in India and the UK providing molecular oncology diagnostic tests. Revenue is generated on a per-test basis for each diagnostic service performed (e.g., CellDx-Tissue, Trublood, EasyCheck360, Exacta, Chemoscale, Cancertrack, Target-MRD, Pinaka). Tests are ordered by clinicians and paid for by patients or healthcare systems.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Datar Cancer Genetics operates CAP-accredited and CLIA-certified clinical laboratories in India and the UK that deliver non-invasive cancer diagnostic tests spanning the entire continuum of care. Its offering covers early multi-cancer blood-based screening (EasyCheck360), risk-free blood-based biopsy for tumour detection (Trublood), comprehensive genomic profiling from tumour tissue (CellDx-Tissue) and blood (Exacta, Pinaka), in-vitro chemotherapy response profiling on live tumour cells (Chemoscale), and real-time molecular monitoring for recurrence and residual disease (Cancertrack, Target-MRD). Tests are ordered by clinicians for patients or directly requested by patients through the company website, with results delivered as clinically actionable reports guiding personalised therapy selection.

Product overview

Datar Cancer Genetics offers a comprehensive portfolio of non-invasive blood-based cancer diagnostic tests spanning the entire cancer care continuum. The core offerings include EasyCheck360 for early cancer screening in asymptomatic individuals, Trublood for risk-free tumor detection as an alternative to traditional biopsies, and a suite of therapy guidance solutions including CellDx-Tissue (FDA-cleared comprehensive genomic profiling), Exacta (multi-analyte tumor analysis), Pinaka (biomarker evaluation), and Chemoscale (in-vitro chemosensitivity testing). For ongoing patient management, Cancertrack enables real-time non-invasive cancer monitoring while Target-MRD provides molecular residual disease detection. The company operates CAP-accredited and CLIA-certified laboratories in India and the UK, with products CE-marked for the EU market.

Differentiator

Problem solved

Functional benefit

Brands

• EasyCheck360: Non-invasive blood test for early cancer screening in asymptomatic individuals, detecting circulating tumour cells to identify multiple cancer types at early stages.
• Trublood
• Exacta
• CellDx-Tissue
• Chemoscale
• Cancertrack
• Target-MRD
• Pinaka

Products and services

• EasyCheck360 Non-invasive blood test for early cancer screening in asymptomatic individuals that detects Circulating Tumour Cells (CTCs) using immunocytochemistry to identify up to 30 different types of solid organ cancers at early stages (Stage 0, I, II).
• Trublood Non-invasive blood-based biopsy using immunocytochemistry (ICC) staining to detect Circulating Tumour Cells (CTCs) for tumour detection in suspected cases of solid and brain tumours, offering a risk-free alternative to traditional tissue biopsies.
• CellDx-Tissue FDA-cleared tissue-based comprehensive genomic profiling assay for solid tumours that analyzes 517 cancer-associated genes using dual DNA and RNA targeted next-generation sequencing to detect SNVs, MNVs, InDels, ERBB2 amplification, and RNA-based gene fusions for personalised treatment guidance.
• Exacta Multi-analyte comprehensive tumour analysis integrating genomic alterations in 400 genes and perturbations in expressions of 20,802 genes to identify actionable mutations and pathways for personalised treatment strategies, including drug toxicity profile and chemosensitivity analysis.
• Pinaka Non-invasive blood test that detects Circulating Tumour Cells (CTCs) and analyzes key biomarkers using immunocytochemistry (ICC) and FISH to guide personalised cancer treatment when tissue samples are unavailable.
• Chemoscale Non-invasive in-vitro chemosensitivity test that isolates tumour cells from blood or tissue samples and analyzes them against different chemotherapy drugs to predict efficacy and resistance, guiding personalised chemotherapy selection.
• Cancertrack Non-invasive blood test for real-time cancer monitoring that detects DNA and RNA released by cancer cells in the bloodstream to track recurrence or changes in tumour characteristics without requiring tissue samples.
• Target-MRD Advanced blood test for molecular residual disease (MRD) monitoring that combines tumour-informed and tumour-agnostic profiling for early detection of recurrence and treatment effectiveness tracking.

Quantifiable outcome

• EasyCheck360 can detect CTCs at Stage 0, I, and II cancers with high accuracy across up to 30 cancer types.
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Partnerships

Four partnerships are on record, tiered regional, core and minor.

• Virtus GroupregionalChannel Partner/ Reseller/ Distributor · 1 January 2022Virtus Group announced a partnership with Datar Cancer Genetics to offer personalised precision oncology solutions in Kuwait. Virtus Group serves as the channel partner distributing Datar Cancer Genetics' testing services within the Kuwait market.
• Cromwell HospitalcoreStrategic or Co-development PartnerCromwell Hospital, a world-leading private hospital in London, serves as a trusted second opinion partner for Datar Cancer Genetics. The partnership enables Cromwell Hospital to offer Datar Cancer Genetics' non-invasive cancer testing services to its patients, providing access to advanced precision oncology diagnostics.
• The London CliniccoreStrategic or Co-development PartnerThe London Clinic partnered with Datar Cancer Genetics to offer enhanced cancer testing services to its patients. This partnership provides The London Clinic's patients with access to Datar Cancer Genetics' comprehensive suite of non-invasive cancer diagnostics including screening, diagnosis, therapy guidance, and monitoring.
• Dr. Massimo CristofanilliminorOthersDr. Massimo Cristofanilli, MD, FACP, a renowned expert in precision oncology and early cancer detection, joined Datar Cancer Genetics as a Strategic Advisor. He brings clinical and scientific expertise to guide the company's strategic direction and scientific programmes.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Guardant Health: Guardant Health is a leading US liquid biopsy company offering NGS-based blood tests for cancer screening, therapy selection, and MRD monitoring. Direct competitor to Datar's EasyCheck360, Trublood, Exacta, and Target-MRD products.
• Foundation Medicine: Foundation Medicine (a Roche subsidiary) is the established leader in tissue-based comprehensive genomic profiling with FDA-authorized FoundationOne CDx and FoundationOne Liquid CDx. Direct competitor to CellDx-Tissue and the broader liquid biopsy portfolio.
• Natera: Natera is a leading cell-free DNA testing company with a strong MRD franchise (Signatera) and oncology molecular testing. Direct competitor to Datar's Target-MRD, CellDx-Tissue, and cancer monitoring tests.
• Tempus AI: Tempus AI offers NGS-based molecular profiling, liquid biopsy, and AI-driven clinical decision support for oncology. Direct competitor across Datar's therapy guidance, CGP, and Exacta AI platform offerings.
• Caris Life Sciences: Caris Life Sciences provides tissue-based CGP (MI Profile) and liquid biopsy profiling with proprietary AI/molecular science platforms. Closely comparable to Datar's CellDx-Tissue, Exacta, and Chemoscale offerings.
• Personalis: Personalis offers the NeXT Personal tumor-informed liquid biopsy MRD test alongside its ImmunoID Next tissue-based CGP platform. Direct competitor in CGP and MRD where Datar's CellDx-Tissue and Target-MRD compete.
• NeoGenomics: NeoGenomics is a US oncology-focused clinical laboratory offering comprehensive genomic profiling, liquid biopsy, and MRD services. Direct competitor in CGP, therapy selection, and oncology monitoring diagnostics.
• OncoDNA: OncoDNA is a Belgium-based molecular oncology company offering comprehensive genomic profiling, liquid biopsy, and treatment recommendation services across Europe and emerging markets. Comparable international footprint and CGP/liquid biopsy focus.

Broad incumbents

• Exact Sciences: Exact Sciences is a leading molecular diagnostics company with the Cologuard multi-cancer screening test and an expanding oncology franchise (Oncotype, PreventionGenetics). Comparable in multi-cancer early detection and therapy guidance strategy.

Emerging players

• Burning Rock Biotech: Burning Rock Biotech is a China-based NGS oncology company providing liquid biopsy CGP and cancer therapy selection tests for biopharma and clinicians. Comparable technology platform and biopharma services focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/datargenetics
• Facebookfacebook.com/DatarGeneticsLimited
• LinkedInlinkedin.com/company/datar-genetics-limited

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Datar Genetics